All Videos

Neal Bhatia, MD, explains why photodynamic therapy's ability to target subclinical damage across the entire field makes it one of dermatology's most powerful chemopreventive tools.

Maryanne Makredes Senna, MD, discusses emerging data suggesting extended-release oral minoxidil tablets may improve efficacy while minimizing cardiovascular adverse effects in patients with androgenetic alopecia.

Neal Bhatia, MD, makes the case for photodynamic therapy as a versatile, field-treating option, not just an alternative to surgery.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Once-daily roflumilast cream brings fast itch relief, EASI-75 responses, and reassuring safety in 3–24 months, supporting a recent sNDA to the FDA.

Daniel Condie, MD, shares kid-friendly sun safety tips, tanning bed warnings, and early skin cancer detection advice that clinicians can share with families and teens.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Daniel Condie, MD, debunks common Gen Z tanning myths, warns base tans and sunscreen fears fuel early skin cancer, and explains Mohs care challenges.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress, including laughter yoga, relationships, and mindset shifts

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress — from family time and fitness to emotional intelligence training and even Botox.

Allergist and bestselling author Zachary Rubin, MD, joins host Renata Block, DMSc, MMS, PA-C, to debunk common allergy and atopic dermatitis myths and explore the immunology of the atopic march, cross-specialty collaboration, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

Many participants in the mobile screening program have never previously seen a dermatologist.

Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.

GLP-1 agonists may aid psoriasis, wound healing, and cardiometabolic health—Daniel Walker, MD, FAAD, explains why dermatologists should start to pay attention.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

April Armstrong, MD, MPH, discusses the role of itch as a key driver of psoriasis burden and shows how next-generation oral TYK2 inhibitors like envudeucitinib provide rapid symptom relief and meaningful improvements in quality of life.

April Armstrong, MD, MPH, highlights envudeucitinib as a next-generation oral TYK2 inhibitor that delivers biologic-level efficacy and strong safety, expanding treatment options for patients with moderate to severe psoriasis.

April Armstrong, MD, MPH, reframes psoriasis as a systemic inflammatory disease and highlights a shift toward earlier systemic treatment, with emerging oral therapies like TYK2 inhibitors offering improved efficacy and safety.

Kristen Lo Sicco, MD, shares why scarring alopecia can’t wait as LPP demands early treatment to prevent permanent hair loss amid limited FDA-approved options.

GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.

Discover how HS clinicians track real-life progress, set 3–4 month treatment goals, and build trust with patient-centered questions and empathy.

Dermatologists are exploring GLP-1 drugs for psoriasis and HS, but evidence is early—weight-loss benefits may help as add-ons, not replacements.

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

At AAD 2026, Lauren Madigan, MD, presented long-term PIONEER trial extension data and urged clinicians to sharpen their recognition of 2 clonally driven inflammatory diseases: indolent systemic mastocytosis and VEXAS syndrome.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss phase 3 data presented at AAD showing patients moving from very severe disease at baseline to absent or mild disease by week 40.